



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 10th November, 2020

To
National Stock Exchange of India Limited
Exchange Plaza
Plot No. C/1, G Block
Bandra Kurla Complex
Bandra (E), Mumbai- 400051

To
Bombay Stock Exchange Limited
Phiroze Jejeebhoy Towers
Rotund Bldg., Dalal Street
Mumbai- 400001

SYMBOL: PDPL

Scrip Code: 524689

Subject:- Submission of Unaudited Financial Results for the Quarter and half year ended on 30th September, 2020


Dear Sir/Ma'am

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Unaudited Financial Results of the Company (on both Standalone and Consolidated basis) for the quarter and half year ended 30th September, 2020.

This is for the information of the Exchange and Members thereof.

Kindly take the same on record.

Thanking You
for **Parenteral Drugs (India) Limited**


Suruchi Maheshwari
Company Secretary and Compliance Officer





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020

		(Rs in Lakh, unless otherwise stated)					
Sr. No.	Particulars	Quarter Ended 30-09-2020 (Unaudited)	Quarter Ended 30-06-2020 (Unaudited)	Quarter Ended 30-09-2019 (Unaudited)	Year to Date 30-09-2020 (Unaudited)	Year to Date 30-09-2019 (Unaudited)	Year Ended 31-03-2020 (Audited)
	Income						
I	(a) Revenue From Operation (Gross)	464.14	291.89	734.31	756.03	1,605.91	3,187.48
II	(b) Other Operating Income	1.38	1.18	1.80	2.56	3.10	25.18
III	Total Income (I+II)	465.52	293.07	736.11	758.59	1,609.01	3,212.66
IV	Expenditure						
	Cost of Material Consumed	219.90	152.73	170.88	372.63	322.64	518.40
	Purchase of Stock In Trade	-	-	-	-	-	-
	Change in Inventories of Finished Goods, Stock In Trade and Work in Progress	86.46	(58.46)	(1.35)	28.00	108.19	113.70
	Employee Benefit Expenses	488.55	439.53	451.58	928.08	907.20	1,920.56
	Finance costs	3,103.30	2,985.21	2,716.15	6,088.51	5,315.34	10,995.57
	Depreciation, Amortisation and Impairment Expense	433.65	433.64	434.31	867.29	868.61	1,734.59
	Other Expenditure	315.85	340.78	479.15	656.63	1,031.18	2,103.17
	Total Expenses (IV)	4,647.71	4,293.43	4,250.71	8,941.14	8,553.15	17,385.99
V	Profit / (Loss) before exceptional items and Tax (I-IV)	(4,182.19)	(4,000.36)	(3,514.61)	(8,182.55)	(6,944.15)	(14,173.33)
VI	Exceptional items	-	-	-	-	-	-
VII	Profit / (Loss) before Tax (V-VI)	(4,182.19)	(4,000.36)	(3,514.61)	(8,182.55)	(6,944.15)	(14,173.33)
VIII	Tax Expenses (1) Current Tax (2) Deferred Tax	(814.75)	(778.51)	(683.22)	(1,593.26)	(1,344.15)	(2,766.34)
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(3,367.44)	(3,221.85)	(2,831.39)	(6,589.29)	(5,600.00)	(11,406.99)
X	Net Profit / (Loss) for the period from discontinuing operations	-	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-	-
XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(3,367.44)	(3,221.85)	(2,831.39)	(6,589.29)	(5,600.00)	(11,406.99)
XIV	Other Comprehensive Income						
	A (i) Item that will not be reclassified to Profit or loss	(4.38)	(7.83)	(0.19)	(12.21)	(1.67)	(31.20)
	(ii) Income tax relation to Item that will not be reclassified to Profit or loss	-	-	-	-	-	-
	B (i) Item that will be reclassified to Profit or loss	-	-	-	-	-	-
	(ii) Income tax relation to Item that will be reclassified to Profit or loss	-	-	-	-	-	-
	Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period)	(3,371.82)	(3,229.68)	(2,831.58)	(6,601.50)	(5,601.67)	(11,438.19)
XV	Paid Up Equity share capital(Face value Rs.10/-each)	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63
XVII	Earnings per share (for continuing operation):						
	(a) Basic (In Rs)	(11.31)	(10.83)	(9.50)	(22.14)	(18.79)	(38.36)
	(b) Diluted (In Rs)	(11.31)	(10.83)	(9.50)	(22.14)	(18.79)	(38.36)
XVIII	Earnings per share (for discontinued operation):						
	(a) Basic (In Rs)	-	-	-	-	-	-
	(b) Diluted (In Rs)	-	-	-	-	-	-
XIX	Earnings per share (for discontinued & continuing operation):						
	(a) Basic (In Rs)	(11.31)	(10.83)	(9.50)	(22.14)	(18.79)	(38.36)
	(b) Diluted (In Rs)	(11.31)	(10.83)	(9.50)	(22.14)	(18.79)	(38.36)






PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

		AMOUNT RS. IN LAKHS	
Statement of Assets and Liabilities:		STANDALONE	
Sr. No.	Particulars	As at 30-09-2020 (Unaudited)	As at 31-03-2020 (Audited)
I.	ASSETS		
(1)	Non-current assets		
	(a) Property, plant and equipment	33,046.77	33,914.06
	(b) Intangible assets	-	-
	(c) Financial Assets		
	(i) Investments	257.85	257.85
	(ii) Loans	279.18	278.93
	(iii) Others	-	-
	(d) Other non-current assets	610.78	607.05
	(e) Deferred tax assets(Net)	14,909.72	13,312.17
	Total Non-current assets	49,104.30	48,370.06
(2)	Current assets		
	(a) Inventories	48.90	125.54
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Cash and cash equivalents	6.91	10.73
	(iv) Bank balances ther than (iii) above	-	-
	(v) Loans	860.34	846.74
	(c) Other Current Assets	5,714.30	5,690.87
	Total Current assets	6,630.45	6,673.88
	Total Assets	55,734.75	55,043.94
II.	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	2,981.63	2,981.63
	(b) Other Equity	(65,746.22)	(59,144.71)
	Total Equity	(62,764.59)	(56,163.08)
(1)	LIABILITIES		
	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	10,623.51	10,623.51
	(ii) Other financial liabilities	-	-
	(b) Other non-current liabilities	12.75	13.50
	Total Non-Current Liabilities	10,636.26	10,637.01
(2)	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	711.85	792.98
	(iii) Other financial liabilities	97,628.55	91,570.14
	(b) Other current liabilities	8,514.39	7,261.31
	(c) Provisions	1,008.29	945.58
	Total Current liabilities	107,863.08	100,570.01
	Total Equity and Liabilities	55,734.75	55,043.94



DRS is Accredited by

JAS-ANZ





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

CASH FLOW STATEMENT	AMOUNT RS. IN LAKHS	
	STANDALONE	
Particulars	As at 30-09-2020 (Unaudited)	As at 31-03-2020 (Audited)
Profit/(Loss) before tax	(8,182.56)	(14,173.33)
Adjustments to reconcile profit before tax to net cash used in operating activities		
Depreciation and impairment of property, plant and	867.29	1,734.58
Remeasure of the defined benefit plans	(16.50)	(42.16)
Equity Instruments directly taken to OCI	0.00	0.00
Finance income	(2.34)	(7.89)
Finance costs	6,088.51	10,995.57
Provision for Gratuity and compensated absences	62.71	107.91
Operating profit before working capital changes	(1,182.89)	(1,385.32)
Working capital adjustments		
(Increase)/ Decrease in inventories	76.64	271.52
(Increase)/ Decrease in trade and other receivables	0.00	0.00
(Increase)/ Decrease in other assets	(27.16)	(32.69)
(Increase)/ Decrease in Other Balance with Banks	0.00	35.09
Decrease/(Increase) in Long-term loans & advances	(13.85)	(358.18)
Increase/ (Decrease) in trade and other payables	(81.13)	(393.99)
Increase/ (Decrease) in other liabilities	7,310.74	13,100.08
Cash generated from operations	6,082.35	11,236.51
Income Tax paid	0.00	0.00
Net cash flows from operating activities	6,082.35	11,236.51
Cash flow from investing activities		
Payment for purchase and construction of property, plant and	0.00	0.00
Purchase of Investments	0.00	0.00
Interest received	2.34	7.89
Net cash flows from investing activities	2.34	7.89
Cash flow from financing activities		
Proceeds from issue of share capital	0.00	0.00
Increase/(decrease) in Short Term Borrowings	0.00	0.00
Increase/(decrease) in Long Term Borrowings	0.00	(247.54)
Finance Costs	(6,088.51)	(10,995.57)
Net cash flows from financing activities	(6,088.51)	(11,243.11)
Net increase / (decrease) in cash and cash equivalents	(3.82)	1.29
Cash and cash equivalents at the beginning of the year	10.72	9.43
Effect of exchanges rate changes on cash and cash	0.00	0.00
Cash and cash equivalents at the end of the year	6.90	10.72
Reconciliation of Cash and Cash equivalents with the Balance Sheet		
Cash and Bank Balances as per Balance Sheet		
Cash on hand	0.11	0.05
Bank balances	6.79	10.67
Cash and Cash equivalents as restated as at the year end	6.90	10.72



DRS is Accredited by
IAS-ANZ 7 MCH0001712

JAS-ANZ





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

- 1 The above results were reviewed by the audit committee at their meeting held on 10-11-2020 and thereafter approved by Board of Directors at their meeting held on 10-11-2020.
- 2 The statutory auditors of the company have carried out limited review of the aforesaid results.
- 3 The above standalone financial results for the quarter and half year ended on 30 th September 2020 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017, the Company has for the first time adopted Ind AS with the transition date of April 1, 2016
- 4 At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- 5 The previous period figures have been regrouped/rearranged wherever found necessary.
- 6 The Standalone financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors




Vinod Kumar Gupta
Managing Director

DIN: 00039145

Place: Indore

Date: 10th November 2020



DRS is Accredited by





Limited Review Report of unaudited standalone financial result for the quarter and half year ended on 30th September 2020

Review report to The Board of Directors of Parenteral Drugs (India) Limited

We have reviewed the accompanying statement of unaudited financial results of Parenteral Drugs (India) Limited for the quarter ended 30th September 2020 and year to date results for the period from 1st April 2020 to 30th September, 2020 ("the Statement"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singhal Jain & Co.
Chartered Accountants
Firm Regn No.013995C

Kamal Jain
(Partner)
M. No.406604



Place: Jaipur
Date : 10.11.2020

UDIN: 20406604AAAA07233



PARENTERAL DRUGS (INDIA) LIMITED


Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020

		(Rs in Lakh)					
Sr. No.	Particulars	Quarter Ended 30-09-2020 (Unaudited)	Quarter Ended 30-06-2020 (Unaudited)	Quarter Ended 30-09-2019 (Unaudited)	Year to Date 30-09-2020 (Unaudited)	Year to Date 30-09-2019 (Unaudited)	Year Ended 31-03-2020 (Audited)
I	(a) Revenue From Operation	464.14	291.89	734.31	756.03	1605.91	3187.48
II	(b) Other Income	1.38	1.18	1.80	2.56	3.10	25.18
III	Total Income (I+II)	465.52	293.07	736.11	758.59	1609.01	3212.66
IV	Expenditure						
	Cost of Material Consumed	219.90	152.73	170.88	372.63	322.64	518.40
	Purchase of Stock In Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Change in Inventories of Finished Goods, Stock In trade and Work in Progress	86.46	-58.46	-1.35	28.00	108.19	113.70
	Employee Benefit Expenses	488.55	439.53	451.58	928.08	907.20	1920.56
	Finance costs	3103.30	2985.21	2716.15	6088.51	5315.34	10995.62
	Depreciation and Amortisation Expenses	433.65	433.64	434.31	867.29	868.61	1734.59
	Other Expenditure	315.85	340.78	479.15	656.63	1031.18	2103.39
	Total Expenses (IV)	4647.71	4293.43	4250.71	8941.14	8553.15	17386.26
V	Profit / (Loss) before exceptional items and Tax (I-IV)	(4,182.19)	(4,000.36)	(3,514.61)	(8,182.55)	(6,944.15)	(14,173.60)
VI	Exceptional items	-	-	-	-	-	-
VII	Profit / (Loss) before Tax (V-VI)	(4,182.19)	(4,000.36)	(3,514.61)	(8,182.55)	(6,944.15)	(14,173.60)
VIII	Tax Expenses						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-814.75	-778.51	-683.22	-1593.26	-1344.15	-2766.34
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(3,367.44)	(3,221.85)	(2,831.39)	(6,589.29)	(5,600.00)	(11,407.26)
X	Net Profit / (Loss) for the period from discontinuing operations	-	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-	-
XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(3,367.44)	(3,221.85)	(2,831.39)	(6,589.29)	(5,600.00)	(11,407.26)
XIV	Other Comprehensive Income						
	A (i) Item that will not be reclassified to Profit or loss	-4.38	-7.83	-0.19	-12.21	-1.67	-31.20
	(ii) Income tax relation to Item that will not be reclassified to Profit or loss	-	-	-	-	-	-
	B (i) Item that will be reclassified to Profit or loss	-	-	-	-	-	-
	(ii) Income tax relation to Item that will be reclassified to Profit or loss	-	-	-	-	-	-
XV	Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period)	(3,371.82)	(3,229.68)	(2,831.58)	(6,601.50)	(5,601.67)	(11,438.46)
XVI	Paid Up Equity share capital(Face value Rs.10/-each)	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63
XVII	Earnings per share (for continuing operation) :						
	(a) Basic	(11.31)	(10.83)	(9.50)	(22.14)	(18.79)	(38.36)
	(b) Diluted	(11.31)	(10.83)	(9.50)	(22.14)	(18.79)	(38.36)
XVIII	Earnings per share (for discontinued operation) :						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XIX	Earnings per share (for discontinued & continuing operation) :						
	(a) Basic	(11.31)	(10.83)	(9.50)	(22.14)	(18.79)	(38.36)
	(b) Diluted	(11.31)	(10.83)	(9.50)	(22.14)	(18.79)	(38.36)





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

		AMOUNT RS. LAKHS	
Statement of Assets and Liabilities:		Consolidated	
Sr. No.	Particulars	As at 30-09-2020 (Unaudited)	As at 31-03-2020 (Audited)
I.	ASSETS		
(1)	Non-current assets		
	(a) Property, plant and equipment	33,046.77	33,914.07
	(b) Intangible assets	-	-
	(c) Financial Assets	-	-
	(i) Investments	240.10	240.10
	(ii) Loans	279.18	278.93
	(iii) Others	-	-
	(d) Other non-current assets	697.01	693.28
	(e) Deferred tax assets(net)	14,909.72	13,312.17
	Total Non-current assets	49,172.78	48,438.55
(2)	Current assets		
	(a) Inventories	48.90	125.54
	(b) Financial Assets	-	-
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Cash and cash equivalents	7.00	10.81
	(iv) Bank balances ther than (iii) above	-	-
	(v) Loans	860.34	904.07
	(c) Other Current Assets	5,786.88	5,706.12
	Total Current assets	6,703.12	6,746.54
	Total Assets	55,875.90	55,185.09
II.	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	2,981.63	2,981.63
	(b) Other Equity	(65,713.74)	(59,112.23)
	Total Equity	(62,732.11)	(56,130.60)
	Minority Interest	12.25	12.25
(1)	LIABILITIES		
	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	10,719.78	10,719.78
	(ii) Other financial liabilities	-	-
	(b) Other non-current liabilities	12.75	13.50
	Total Non-Current Liabilities	10,732.53	10,733.28
(2)	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	712.00	793.13
	(iii) Other financial liabilities	97,628.55	91,570.14
	(b) Other current liabilities	8,514.39	7,261.31
	(c) Provisions	1,008.29	945.58
	Total Current liabilities	107,863.23	100,570.16
	Total Equity and Liabilities	55,875.90	55,185.09





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

CASH FLOW STATEMENT	AMOUNT RS. IN LAKHS	
	Consolidated	
Particulars	As at 30-09-2020 (Unaudited)	As at 31-03-2020 (Audited)
Cash flow from operating activities		
Profit/(Loss) before tax	(8,182.55)	(14,173.61)
Adjustments to reconcile profit before tax to net cash used in operating activities		
Depreciation and impairment of property, plant and equipment	867.29	1,734.58
Remeasure of the defined benefit plans	(16.50)	(42.16)
Equity Instruments directly taken to OCI	-	-
Finance income	(2.34)	(7.89)
Finance costs	6,088.51	10,995.62
Provision for Gratuity and compensated absences	62.71	107.91
Operating profit before working capital changes	(1,182.88)	(1,385.55)
Working capital adjustments		
(Increase)/ Decrease in inventories	76.64	271.52
(Increase)/ Decrease in trade and other receivables	-	-
(Increase)/ Decrease in other assets	(84.49)	(33.18)
(Increase)/ Decrease in Other Balance with Banks	-	35.10
Decrease/(Increase) in Long-term loans & advances	43.48	(357.59)
Increase/ (Decrease) in trade and other payables	(81.13)	(394.06)
Increase/ (Decrease) in other liabilities	7,310.74	13,100.09
Cash generated from operations	6,082.36	11,236.33
Income Tax paid	-	-
Adjusted due to closure of subsidiaries	-	-
Net cash flows from operating activities	6,082.36	11,236.33
Cash flow from investing activities		
Payment for purchase and construction of property, plant and equipment	-	-
Purchase of Investments	-	-
Interest received	2.34	7.89
Net cash flows from investing activities	2.34	7.89
Cash flow from financing activities		
Proceeds from issue of share capital	-	-
Increase/(decrease) in Short Term Borrowings	-	(247.32)
Increase/(decrease) in Long Term Borrowings	-	(10,995.62)
Finance costs	(6,088.51)	(10,995.62)
Net cash flows from financing activities	(6,088.51)	(11,242.94)
Net increase / (decrease) in cash and cash equivalents	(3.81)	1.28
Cash and cash equivalents at the beginning of the year	10.81	9.53
Effect of exchanges rate changes on cash and cash equivalents	-	-
Cash and cash equivalents at the end of the year	7.00	10.81
Reconciliation of Cash and Cash equivalents with the Balance Sheet		
Cash and Bank Balances as per Balance Sheet		
Cash on hand	0.11	0.05
Bank balances	6.89	10.76
Cash and Cash equivalents as restated as at the year end	7.00	10.81





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

- The above results were reviewed by the audit committee at their meeting held on 10-11-2020 and thereafter approved by Board of Directors at their meeting held on 10-11-2020.
- The statutory auditors of the company have carried out limited review of the aforesaid results.
- Additional information on standalone financial results are given below:

Particulars	Rs. In Lakh					
	Quarter Ended	Quarter Ended	Quarter Ended	Year to Date	Year to Date	Year ended
	30-09-2020	30-06-2020	30-09-2019	30-09-2020	30-09-2019	31-03-2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from operations	465.52	293.07	736.11	758.59	1,609.01	3,212.66
Profit/Loss before tax	(4,182.19)	(4,000.36)	(3,514.61)	(8,182.55)	(6,944.15)	(14,173.33)
Profit/Loss after tax	(3,371.82)	(3,229.68)	(2,831.58)	(6,601.50)	(5,601.67)	(11,438.19)

- The Consolidated financial results for the quarter and half year ended on September 30, 2020 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017, the Company has for the first time adopted Ind AS with the transition date of April 1, 2016.
- At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- The previous period figures have been regrouped/rearranged wherever found necessary.
- The Consolidated financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors

Place: Indore
Date: 10th November 2020



Vinod Kumar Gupta
Managing Director
DIN : 00039145





Independent Auditor's Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**TO THE BOARD OF DIRECTORS OF
Parenteral Drugs (India) Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Parenteral Drugs (India) Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter ended 30th September, 2020 and for the period from 1st April, 2020 to 30th September, 2020 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities: Parenteral Drugs (India) Limited, Parenteral Impex Limited, Parenteral Biotech Limited.





5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statements /financial information/ financial results of of two Subsidiaries included in the consolidated unaudited financial results, whose interim financial statements/ financial information/ financial results reflect total revenue of Rs. Nil and Rs. Nil, total net profit/(loss) after tax of Rs. Nil and Rs. Nil and total comprehensive income / loss of Rs. Nil and Nil for the quarter ended 30th September .2020 and for the period from 1st April, 2020 to 30th September, 2020 and cash flows (net) of Rs. Nil for the period from 1st April 2020 to 30th September, 2020 as considered in the respective standalone unaudited/ audited interim financial statements/ financial information/ financial results of the entities included in the Group.as considered in the consolidated unaudited financial results. whose interim financial statements / financial information/ financial results have not been reviewed by us. These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.

For Singhal Jain & Co.
Chartered Accountants
Firm Regn No.013995C




Kamal Jain
(Partner)
M. No.406604

Place: Jaipur

Date : 10.11.2020

UDIN: 20406604 AAAA07233